Every material Form 8-K PRECIGEN, INC. has filed with the SEC since June 24, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Precigen reported third quarter 2026 results for the period ended September 30, 2026. Total revenues were $74.1 million, up $71.2 million from a year earlier, mainly from commercial sales of PAPZIMEOS after its August 2025 FDA approval, and the company posted net income of $35.8 million, or $0.08 per diluted share, compared with a net loss attributable to common shareholders of $325.3 million in the prior-year quarter. Operating cash flow was positive at $11.9 million, a full quarter ahead of the company's guidance.
Total revenues $74.1 million versus $2.9 million a year earlier; PAPZIMEOS net product revenue was $72.9 million, up 37% from the prior quarter.
Net income $35.8 million, or $0.08 per diluted share, versus a prior-year net loss attributable to common shareholders of $325.3 million that included a $111.5 million warrant liability charge and a $179.0 million deemed dividend.
Net cash provided by operating activities was $11.9 million in the third quarter, which the company said was a full quarter ahead of its guidance.
Cash, cash equivalents and investments totaled $51.0 million as of September 30, 2026.
Precigen reported second quarter 2026 total revenues of $55.0 million, up from $856,000 a year earlier, driven by commercial sales of PAPZIMEOS, and net income of $20.1 million, or $0.05 per diluted share, compared with a net loss of $26.6 million a year earlier. The company said the quarter marked its first profitable quarter and that cash, cash equivalents and investments of $38.7 million as of June 30, 2026 are expected to support cash flow break-even by the end of 2026.
Q2 2026 total revenues were $55.0 million, including $53.1 million from PAPZIMEOS sales, versus $856,000 in Q2 2025.
Q2 2026 net income was $20.1 million, or $0.06 per basic and $0.05 per diluted share, compared with a net loss of $26.6 million in Q2 2025.
SG&A expenses rose $6.1 million year over year, mainly from PAPZIMEOS commercial activities; R&D fell $4.2 million, mainly from an accounting change for PAPZIMEOS manufacturing costs.
Cash, cash equivalents and investments totaled $38.7 million as of June 30, 2026, and the company expects cash flow break-even by the end of 2026.
At its June 18, 2026 annual meeting, Precigen stockholders approved an amendment adding 7 million shares to the 2023 Omnibus Incentive Plan for equity awards. The same meeting re-elected all nine directors, ratified Deloitte & Touche LLP as auditor for fiscal 2026, and approved the non-binding executive pay resolution, so the plan change is the only item that affects the share pool.
Plan amendment approved: 207,056,264 for, 4,996,260 against, 234,326 abstain, with 61,452,809 broker non-votes
All nine directors were elected to one-year terms, including Randal Kirk and Nancy Howell Agee
Deloitte & Touche LLP ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 272,813,907 votes for
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PRECIGEN, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →